EVMN Evommune, Inc.
NEUTRAL
Impact: 3/10
8-K
8-K context-dependent: Items 7.01
Latest settled — T+20d
EVMN ▼ -12.84% at T+20d
NEUTRAL call ✗ call lost -12.84% · α vs SPY -19.14% · entry $26.63 → $23.21
Last close $19.83 (close Jun 12) · -25.54% from $26.63 entry
T+1d
+1.16%
call +1.16% · α +0.39%
$26.94
settled 2mo ago
T+5d
+5.41%
call +5.41% · α +4.01%
$28.07
settled 8w ago
T+20d
-12.84%
call -12.84% · α -19.14%
$23.21
settled 5w ago
T+60d
—
call — · α —
—
in 23d
Price Chart
Loading chart...
Executive Summary
Evommune hosted a webcast on April 13, 2026, highlighting its EVO756 program targeting MRGPRX2 for migraine treatment, including plans for a Phase 2b trial in mid-2026. The filing is a standard Regulation FD disclosure of a public presentation.
Actionable Insight
Monitor for actual clinical data from the upcoming Phase 2b trial, as the webcast provided only forward-looking statements without new results.
Key Facts
- Hosted a webcast on migraine treatment landscape and EVO756's role
- Presentation included forward-looking statements about EVO756's potential and trial timeline
- No new financial data or material updates disclosed
- Filing is routine Regulation FD disclosure of a public event
Financial Impact
No immediate financial impact
Risk Factors
- Forward-looking statements may not materialize
- Clinical trial timelines are subject to change
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152864 |
| Document: evmn-ex99_1.htm | 0001193125-26-152864 |
| Document: 0001193125-26-152864-index-headers.html | 0001193125-26-152864 |
| Document: 0001193125-26-152864-index.html | 0001193125-26-152864 |
| Document: 0001193125-26-152864.txt | 0001193125-26-152864 |
9 reports for EVMN
67%
Hit rate
best @ T+5▲ +14.25%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
11d ago
|
Insider Cluster
| $20.69 $19.92 | ▲ +3.72% | ▲ +1.12% | $19.83 (+4.16%) |
|
Jun 2, 2026
12d ago
|
144
| $19.73 $20.69 | ▲ +4.87% | ▲ +4.47% | $19.83 (+0.51%) |
|
Jun 2, 2026
13d ago
|
Insider Cluster
| $19.82 $19.73 | ▼ −0.45% | ▲ +0.27% | $19.83 (+0.05%) |
|
May 28, 2026
17d ago
|
144
| $23.23 $22.17 | ▲ +4.56% | ▲ +4.82% | $19.83 (+14.64%) |
|
Apr 27, 2026
7w ago
|
EFFECT
| $25.00 $25.58 | ▲ +2.32% | ▲ +2.81% | $19.83 (−20.68%) |
|
Apr 21, 2026
7w ago
|
DEFA14A
| $27.12 $25.84 | ▼ −4.72% | ▼ −4.33% | $19.83 (−26.88%) |
|
Apr 17, 2026
8w ago
|
S-1
| $27.97 $28.07 | ▲ +0.36% | ▲ +1.01% | $19.83 (−29.10%) |
|
Apr 13, 2026
8w ago
|
8-K
| $26.63 $26.94 | ▲ +1.16% | ▲ +0.39% | $19.83 (−25.54%) |
|
Mar 5, 2026
14w ago
|
8-K
| $26.50 $24.61 | ▼ −7.13% | ▼ −7.98% | $19.83 (−25.17%) |
Showing 9 of 9
US Market Status
Market Closed — Opens in 4h 44m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access